DHTKD1 and neoplasm: DNX2401 is an oncolytic Ad with improved infectivity and tumor selectivity [59], achieved by a 24-bp deletion in the Rb binding site of the E1A region, which enables selective replication in cancer cells that lack a functional Rb pathway [60].